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INTRODUCTION 
Nausea  and  vomiting are the most feared  complications of chemotherapy experienced 
by the patients.1,2.Almost 70-80% of all cancer patients will be having chemotherapy induced 
nausea and vomiting.3,4 The prevention of chemotherapy induced nausea and vomiting (CINV) is 
very much important and necessary because it has huge implications on both patient’s and 
clinician’s perspective. As it is the most common problem faced by patients and as it can be 
prevented or controlled to a certain extent with the judicious and careful use of anti emetics sums 
up the significance of the need to select an appropriate anti emetic regimen for a particular class 
of chemotherapy. 
Prevention is always better than cure ,which  is an old age saying holds very true in the 
perspective of CINV also because it is always important to prevent CINV rather than treat CINV 
as damage would have already occurred in the form of poor oral intake, affection of quality of 
life , anxiety in the minds of patients ,creating doubts about their ability to tolerate further 
chemotherapy thus leading to anticipatory vomiting in the subsequent cycles or loss of 
compliance leading to inadequate treatment of the disease and last but not the least the financial 
burden on the individual and the family for supportive care, hospital admission and the rescue 
medications .5 
Treatment  of  breast cancer  also has undergone considerable improvement in the recent 
times leading to increased chance of cure .Hence it becomes extremely important  to provide the 
cure with least toxicities and side effects of treatment. The chemotherapy used in breast cancer 
patients falls under moderately emetogenic chemotherapy type (MEC) 6 . The choice of anti 
emetic regimen in patients treated for highly emetogenic chemotherapy is clear and non 
controversial. The same cannot be told about the anti emetic regimen in patients receiving 
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MEC.7The development of newer anti emetic agents like palonosetron, aprepitant, fosaprepitant 
and casopitant has led to tremendous opportunities and improved patient care. Conventionally 
ondansetron was the anti emetic of choice for patients receiving MEC but now with the advent of 
aprepitant it is becoming the new standard of care as an antiemetic regimen of choice in patients 
receiving MEC especially those receiving a combination of anthracycline and an alkylating 
agent.7 There are only a few trials and studies using aprepitant in patients receiving MEC and in 
fact there are no studies till date comparing palonosetron with aprepitant in the prevention of 
CINV in MEC. Hence our study is a sincere effort in that regard trying to compare palonosetron 
and aprepitant to ondansetron. And we also have compared palonosetron with aprepitant with 
respect to their efficacies in the prevention of CINV .This will be of great help to a limited 
resource country like ours, where a cheaper alternative can be of great relief to the patient 
herself/himself and also to the treating centres and also will have great financial implications If a 
cheaper alternative is obtained. 
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AIM   
 
PRIMARY OUTCOME 
¾ To  compare the Complete response rates in  the ondansetron, palonosetron and 
aprepitant  based antiemetic prophylaxis regimen in patients of breast cancer patients 
receiving moderately emetogenic chemotherapy 
 
SECONDARY OUTCOMES 
¾ To determine the complete response during the acute phase after initiation of 
chemotherapy 
¾ To determine the complete response during the delayed phase after initiation of 
chemotherapy 
¾ To determine the impact of CINV on quality of life using the Functional living Index-
Emesis(FLIE) scores in each of the 3 arms 
¾ To determine the effect of antiemetic agents on the reduction of usage of rescue 
medications   
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REVIEW OF LITERATURE 
“No greater opportunity or obligation can fall the lot of a human being than to be a 
physician .In the care of the suffering he needs technical skill, scientific knowledge, and human 
understanding. He who uses these with courage, humility, and wisdom will provide a unique 
service for his fellow man and will build an enduring edifice of character within himself. The 
physician should ask of his destiny no more than this, and he should be content with no less.” 
Thus every physician has an important role to play in the holistic approach of treatment 
of patients enabling them to lead a better life. Both disease related as well as treatment related 
toxicities have to be tackled in order to improve the quality of life of patients.    
Chemotherapy induced nausea and vomiting being the most common complication needs 
to be treated adequately. Better understanding of the pathophysiology of CINV helps in a more 
efficient control of the same. 
 Inadequately controlled emesis impairs functional activity and quality of life for patients, 
increases the use of health care resources, and may occasionally compromise adherence to 
treatment.5,6,7,8 Chemotherapy plays an important role in the treatment of  various cancers and its 
role remains unquestioned though it comes with its side effects. New insights into the 
pathophysiology of chemotherapy-induced nausea and vomiting, a better understanding of the 
risk factors for these effects, and the availability of new antiemetic agents have all contributed to 
substantial improvements in emetic control. 
 
Pathophysiology of Chemotherapy induced nausea and Vomiting – 
Vomiting can be defined as the oral expulsion of the gastrointestinal contents resulting from 
contractions of the gut and thoracoabdominal wall musculature. Nausea is defined as a subjective 
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unpleasant wave like feeling in the back of the throat and/or stomach that signals imminent 
vomiting 9,10.The vomiting reflex is present in many animal species, ranging  from fish to higher 
mammals, and has been viewed from an evolutionary perspective as a protective mechanism 
against ingested toxins.11,12,13 
The central nervous system plays a critical role in the physiology of nausea and vomiting, 
serving as the primary site that receives and processes a variety of emetic stimuli. The central 
nervous system also plays a primary role in generating efferent signals which are sent to a 
number of organs and tissues in a process that eventually results in vomiting.13,14 
 Pioneering studies conducted by Wang and Borison nearly 60 years ago proposed the 
concept of a central site (vomiting center) located in the medulla that serves as a final common 
pathway for processing all afferent impulses that can initiate emesis.15  It has been mentioned 
that the vomiting centre does not exist as an anatomically distinct site16 but is a collection of 
loosely arranged neuronal tissue in the medulla which coordinates  the emetic reflex. 13,17 These 
neurons which coordinate the complex events of emesis have been designated as complex pattern 
regulator.18 ,19 
Antineoplastic agents  cause emesis through effects at a number of sites. After the 
administration of chemotherapy, free radicals are generated, leading to localized exocytotic 
release of 5-hydroxytryptamine(5-HT) ,substance P and cholecystokinin from the 
enterochromaffin cells. These mediators act on the respective receptors which are located on the 
terminal ends of the vagal afferents. Vagal afferent fibers project to the dorsal brain stem, 
primarily to the nucleus tractus solitarius(NTS), and, to a lesser extent, the area postrema(AP), 
the two parts of the brain referred to collectively  as the dorsal vagal complex. 5HT3, neurokinin 
and dopaminergic  receptors are also present on the dorsal vagal complex. Efferent fibers project 
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from the dorsal vagal complex to the final effector of the emetic reflex, the central pattern 
generator,which is  located more ventrally in the brainstem.7  Antineoplastic agents can also 
induce emesis through direct  interaction with the area postrema within the dorsal vagal complex. 
The area postrema  which is also called as chemoreceptor trigger zone is a circumventricular 
organ located at the caudal end of the floor of the fourth ventricle, which is accessible to blood 
and cerebrospinal fluid–borne emetic stimuli. 20,21,22Other potential sources of efferent input that 
result in emesis after chemotherapy include a number of structures in the temporal lobe, such as 
the amygdala.23,24 Evidence for this pathway is less well established than for other proposed sites 
of chemotherapeutic  action. 
Fig 1- Various neurotransmitters in the pathophysiology of CINV 
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Fig 2 – Patho physiology of CINV 
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Appreciation of the fact that CINV can be divided into distinct emetic clinical syndromes was 
crucial and an important milestone in the rational evolution of anti emetic therapy. This was first 
identified with use of the agent cisplatin. Most important in this regard was the concept of acute 
as compared with delayed emesis, In the absence of effective antiemetic prophylaxis, virtually all 
patients receiving cisplatin will have nausea and vomiting 1 to 2 hours after receiving 
chemotherapy.25 At approximately 18 to 24 hours, the emesis typically subsides, only to recur 
and reach a second peak at approximately 48 to 72 hours after administration  of the agent.26 
Thus CINV is differentiated into three categories: acute onset (mostly serotonin related), 
occurring within 24 hours of initial administration of chemotherapy; delayed onset (in part 
substance P related), occurring 24 hours to several days after initial treatment; and anticipatory, 
observed in patients whose emetic episodes are triggered by taste, odor, sight, thoughts, or 
anxiety secondary to a history of poor response to antiemetic agents or inadequate antiemetic  
prophylaxis in the previous cycle  of chemotherapy.   Anticipatory vomiting usually starts one to 
four hours before chemotherapy but sometimes can occur few days before the administration of  
chemotherapy. 27,28    
Factors affecting CINV- 
                                              Factors determining the occurrence of CINV can be divided into 
patient related and treatment related. Patient related factors are age ,sex, alcohol intake, prior 
history of hyperemesis gravidarum during pregnancy, prior history of motion sickness, type of 
personality with CINV being more common in the younger individuals, females  ,non alcoholics 
, anxious personalities and females with past history of hyper emesis gravidarum.  The treatment 
related factors being the emetogenicity of chemotherapy and the dose of the chemotherapeutic 
agent. 29,30  Chemotherapy agents were classified into 5 groups based on their intrinsic 
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emetogenicity.31  In 2004 it was modified and they were reclassified into four groups namely 
highly emetogenic, moderately emetogenic, low emetogenic and minimal emetogenic. 
 
 
Heskeths classification of level of emetogenicity of chemotherapeutic agents 7 
 
Anti emetic agents 
 The history of anti emetic therapy dates back to 1960s when some antiemetic efficacy on the 
part of phenothiazines  was reported .The introduction of high-dose metoclopramide and 
combination treatment with corticosteroids in the 1980s were significant developments and then 
came  the introduction of serotonin (5-hydroxytryptamine3 [5-HT3]) receptor antagonists into 
clinical practice in the 1990s which was a milestone in the development of anti emetic therapy. 
Currently introduction of a new class of antiemetics neurokinin-1 antagonists and the 
introduction of newer generation of 5HT3 receptor antagonists has revolutionized the anti emetic 
treatment. The available pharmacologic agents for treatment of CINV currently consist of 
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corticosteroids, dopamine antagonists, 5-HT3 receptor antagonists, and NK-1 receptor 
antagonists. 
First-generation 5-HT3 receptor antagonists— dolasetron ,  ondansetron  and  granisetron 
have  been  a  standard  in  preventive  treatment  of  CINV  for  several years. Recent   
guidelines  indicate  that  these  agents  are  therapeutically equivalent, based on the highest level 
of evidence, and that oral and intravenous (IV) doses are equally effective. The introduction of 
the second-generation 5-HT3 antagonist palonosetron and the NK-1 antagonist aprepitant in 
2003 marks what appears to be a significant advance in the management of CINV as  mentioned 
already.32,33 
Newer agents like fosaprepitant, casopitant and others are being  evaluated .                               
Dopamine receptor antagonists 
Three classes of dopamine receptor antagonists may be used in patients with nausea or vomiting: 
Phenothiazines ,Butyrophenones and Benzamides.  
Phenothiazines — The phenothiazines were the first group of drugs to demonstrate substantial 
activity in the prevention of chemotherapy-induced  nausea and vomiting.34 They act 
predominantly by antagonizing D2-dopamine receptors in the area postrema of the midbrain, but 
also have M1-muscarinic and H1-histamine blocking effects.  
Prochlorperazine  is the most commonly used antiemetic in this class; it is moderately effective 
for nausea caused by various gastrointestinal disorders and mild to moderate but not highly 
emetogenic chemotherapy .35,36 However, careful clinical studies of the efficacy of this agent are 
not available, and a placebo effect may occur in nearly 80 percent of patients.35,37 Typical dose 
regimens are 5 to 10 mg PO every six to eight hours, 5 to 10 mg IM or 2.5 to 10 mg IV every 
three to four hours, or 25 mg by rectal suppository every 12 hours.  
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Chlorpromazine  is used less often than prochlorperazine; the dose of this drug is 10 to 25 mg PO 
every four to six hours, 25 mg IV every three to four hours, or 100 mg rectally every six to eight 
hours. Thiethylperazine  is another drug of this class of  antiemetics  which is given at a dose of 
10 mg PO or 2 mg IM every 8 to 24 hours. The main adverse effects of the phenothiazines are 
extrapyramidal reactions such as dystonia and, with prolonged use, tardive dyskinesia. Acute 
dystonia can be treated with diphenhydramine (Benadryl) 25 to 50 mg IM. Hypotension can also 
occur, particularly in the elderly or with intravenous infusion.  
Butyrophenones — Butyrophenones are major tranquilizers that potentiate the actions of opioids 
and have an antiemetic effect when used alone. They are primarily used as a preanesthetic agent 
or for procedural sedation, but are also effective for postoperative nausea and vomiting. 
Butyrophenones have also been used for the treatment of nausea and vomiting in other settings. 
Droperidol , a short-acting drug, is usually given in a dose of 1.25 to 5 mg IM.Haloperidol  also 
can be used but the main disadvantage is its long  half  life  of about 18 hours which limits its 
use.  
The side effect profile and antiemetic efficacy of the butyrophenones appear to be similar 
to those of the phenothiazines. Prior to the advent of the 5-HT receptor antagonists, these agents 
at higher doses were a reasonable alternative to high-dose metoclopramide .38 However, in recent 
years, the need for this class of agents and their utilization have declined.  
Benzamides — Metoclopramide  causes central and peripheral dopamine D2 antagonism at low 
doses, and weak 5-HT3 blockade at the higher doses used for emesis caused by cytotoxic drug 
therapy .36 It also stimulates cholinergic receptors on gastric smooth muscle cells and enhances 
acetylcholine release at the neuromuscular junction.  
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At standard doses, metoclopramide has a modest antiemetic effect .39 It also speeds gastric 
emptying in patients with gastroparesis and increases tone in the lower esophageal sphincter.  
High-dose intravenous metoclopramide combined with dexamethasone and diphenhydramine (to 
counteract the dopaminergic toxicity of metoclopramide) was formerly the antiemetic regimen of 
choice with highly emetogenic chemotherapy.36,40,41 However, it has largely been replaced by the 
5-HT3 receptor antagonists due to their superior efficacy and safety. One problem is that 
metoclopramide crosses the blood-brain barrier. Thus, it commonly causes neurologic side 
effects such as akathisia, dystonia, and tardive dyskinesia, especially in the elderly and at high 
doses.13,42 Metoclopramide is primarily used at present as an adjunctive agent for the prevention 
of cisplatin-induced delayed emesis and with emesis failing first-line treatment.  
Two other benzamides are trimethobenzamide and domperidone. Trimethobenzamide can 
be given at doses of 250 mg PO every six to eight hours or 200 mg IM or by suppository every 
six to eight hours. However, this agent was no better than placebo in one study of patients with a 
variety of illnesses 5, and was only mildly effective in patients receiving chemotherapy in other 
reports .34,43 Prochlorperazine was more effective .34,35  
Domperidone  is a D2-blocker with selective peripheral activity in the upper gastrointestinal 
tract. The major advantage of this drug is that it does not cross the blood-brain barrier and 
therefore lacks the neurologic side effects of metoclopramide. 
5-HT3 Antagonists 
The introduction of selective 5-HT3–receptor  antagonists  in  the  early 1990s  revolutionized 
the  management  of  chemotherapy-induced  nausea  and  vomiting. Currently  five  5-HT3 
antagonists are widely  available namely  ondansetron,   granisetron ,  dolasetron ,  tropisetron   
and  a  more  recently  introduced    palonosetron . These drugs   form  the  cornerstone  of  
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prophylactic  therapy  for  chemotherapy  with  moderate  to high  emetic  potential. Multiple  
prospective   randomized  trials  have  demonstrated  the therapeutic  equivalence 
of the four older 5-HT3 antagonists, which  is  also   supported  by  a  number  of  meta 
analyses.44,45 As  a class,  these  agents  have  few  adverse  effects  of  their  own  and   no   
limiting  toxicity  at  typical  doses. The  most  common  adverse  events   are   mild   headache, 
transient  elevation  of hepatic  aminotransferase   levels, and constipation. Once  daily   
schedules  are  similar  in  efficacy  to  multiple  dose  daily schedules, and  at  the  approved 
doses,  the  oral   formulation   is  therapeutically   equivalent  to  the  intravenous  route of 
administration.46,47 Clinical  trials  with  the  older  5-HT3  antagonists (e.g., granisetron, 
ondansetron),  have  shown  much  lower efficacy for  the  delayed  type  of  chemotherapy-
induced  nausea  and   vomiting  as  compared  with  the  acute  type. These agents appear to 
have  little   activity  when  used  to  prevent   delayed   emesis  induced  by  cisplatin  and  only 
modest activity  when   used  to  prevent  delayed  emesis  induced  by  moderately  emetogenic 
chemotherapy.7 
The  recommended  prophylactic  regimen  for  the  most  emetogenic   chemotherapy  
consists of granisetron (2 mg PO),  ondansetron (16 to 24 mg PO per day)  or dolasetron (100 mg 
PO),  or palonosetron (0.25 mg IV)  combined  with  dexamethasone (12 mg PO)  and aprepitant  
(125 mg PO) 
Another advantage with the 5-HT3 receptor antagonists is a favorable toxicity profile. 
They are generally well tolerated, with mild headache the most frequent adverse event, occurring 
in approximately 15 to 20 percent of patients. Asthenia and constipation occur in 5 to 10 percent, 
and dizziness occurs in approximately 10 percent of patients treated intravenously and in 5 
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percent of those receiving the oral formulation .48 There are no cognitive, psychomotor, or 
affective disturbances .49 
Palonosetron-Palonosetron HCl is an isoquinolone hydrochloride with an empirical formula of 
C19H24N2O HCl and a molecular weight of 332.87.  It is freely soluble in water, soluble in 
propylene glycol, and slightly soluble in ethanol and 2-propanol. Palonosetron injection is a 
sterile, clear, colorless, nonpyrogenic, isotonic, buffered solution for intravenous administration.  
It  is  a  second  generation   5HT3  receptor  antagonist. It differs  from  the previous  generation  
5HT3  receptor  in  its  higher  affinity  and  longer  plasma  half  life. Palonosetron is a highly 
potent, selective, 5-HT3 receptor antagonist with a 5-HT3 receptor binding affinity 
that is 100-fold higher than other 5-HT3 receptor antagonists (pKi 10.5 compared with 8.91 for 
granisetron, 8.81 for tropisetron, 8.39 for ondansetron, 7.6 for dolasetron) 50,51,52 Palonosetron 
also has an extended plasma elimination half-life of  40 h 53 significantly longer than others in its 
class (ondansetron, 4 h 54  tropisetron, 7.3 h 55  dolasetron, 7.5 h  56granisetron, 8.9 h  57  
After intravenous dosing of palonosetron in healthy subjects and cancer patients, an initial 
decline in plasma concentration is followed by a slow elimination from the body. Mean 
maximum plasma concentration and area under the concentration – time curves are generally 
dose-proportional over the dose range of 0.3 to 90 μg/kg in healthy subjects and in cancer 
patients.58 Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg and is 62% 
bound to plasma proteins. Palonosetron is eliminated from the body through renal excretion and 
metabolic pathways. After a single intravenous dose of 10 μg/kg 14C palonosetron, 
approximately 80% of the dose was recovered within 144 hours in the urine with palonosetron 
representing approximately 40% of the administered dose. The mean terminal elimination half-
life is approximately 40 hours . 
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Approximately 50% of palonosetron is metabolized to form two primary metabolites. Each of 
these metabolites has less than 1% of the 5-HT3 receptor antagonist activity of palonosetron. The 
metabolic pathways are mediated via multiple CYP enzymes, including CYP2D6, and to a lesser 
extent, CYP3A and CYP1A2. Clinical pharmacokinetic parameters are not significantly different 
between poor and extensive CYP2D6 metabolizers. The potential for clinically significant drug 
interactions with palonosetron appears to be low.58,59,60 In controlled clinical trials, palonosetron 
has been safely administered with corticosteroids, analgesics, anti-emetics, antispasmodics, and 
anticholinergic agents. Palonosetron did not inhibit the antitumor activity of five 
chemotherapeutic agents (cisplatin, cyclophosphamide, cytarabine, doxorubicin, and mitomycin 
C) in murine tumor models.60 
Population pharmacokinetic analysis did not reveal any differences between cancer patients  
more than 65 years of age and younger patients. Mild to moderate renal impairment does not 
significantly affect palonosetron pharmacokinetics and hepatic impairment does not significantly 
affect total body clearance of palonosetron compared to healthy patients. Therefore, dosage 
adjustment is not necessary for patients with renal or hepatic impairment.59,61 
  Palonosetron is a relatively safe drug  and this has been proved in many phase II 
and phase III trials. Results  from the phase II dose-ranging study and phase III comparative 
studies in patients receiving MEC and HEC were the basis for approval of palonosetron by the 
FDA.62,63,58,64,65 In these studies, patients were exposed to a wide range of palonosetron doses, up 
to 25 times the approved palonosetron dose of 0.25 mg. The adverse reactions reported were the 
most common reactions reported for the 5-HT3 receptor antagonist class, headache, and 
constipation. All other reactions occurred at an incidence of less than1% in patients treated with 
0.25 mg of palonosetron.59,66 There were no clinically relevant differences seen among  
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palonosetron, ondansetron, or dolasetron in laboratory, electrocardiographic, or vital sign 
changes.59 A clinical study in male and female volunteers showed that the cardiac profile of 
palonosetron is the same as placebo. There were no electrocardiographic or dose response 
effects, including QTc prolongation, of palonosetron up to a 2.25 mg iv dose, a 9-fold safety 
margin.67 In phase III studies, palonosetron was safely administered in 192 patients with pre-
existing cardiac impairment.59 The safety of palonosetron administered over repeated cycles of 
MEC or HEC was demonstrated in an open-label multinational phase III study 65,68 Palonosetron 
at 3 times the approved dose was well tolerated over repeated cycles with no unexpected adverse 
events. There were no clinically relevant differences among cycles, and the number of adverse 
reactions did not increase from cycle one to cycle three. 
Corticosteroids 
Corticosteroids were first shown to be effective antiemetic agents more than 25 years ago.69 They 
can be effective when administered as a single agent in patients receiving chemotherapy of low 
emetic potential. They are the mainstay in the prevention of both acute and delayed 
chemotherapy induced nausea and vomiting .They were the most commonly used agents in the 
prevention of CINV as compared to other anti emetics in a large meta analysis which had more 
than 5000 patients.70 Corticosteroids are most beneficial, however, when used in combination 
with other antiemetic agents. This has been well demonstrated  when corticosteroids have been 
used in combination with the 5-HT3–receptor antagonists. 71,72,73 Corticosteroids are effective for 
both acute and delayed emesis.73 Relatively little is known about the site or mechanism of action 
of corticosteroids as compared with the 5-HT3 antagonists and neurokinin-1 antagonists. In 
delayed emesis role of corticosteroids has been very important. Chemotherapy induced enhanced 
cell lysis resulting in release of break down products and various neurotransmitters leads to 
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inflammation and emesis, so this is counteracted by the administration  of corticosteroids and 
this is the basis of efficacy of corticosteroids in delayed emesis.74 
 Many types of corticosteroids have been used as antiemetic agents. The widest experience has 
been reported with dexamethasone and methylprednisolone. Optimal pre chemotherapy dose of 
dexamethasone with highly and moderately emetogenic chemotherapy in prevention of acute 
emesis is well studied 75,76 but optimal dose-ranging data for delayed emesis are lacking. When 
corticosteroids are administered with the moderate cytochrome P-450 3A4 inhibitor aprepitant, 
doses should be reduced by approximately 50% . The only exception would be cases in which 
corticosteroids constitute part of the antineoplastic regimen. In those instances, 
therapeutic corticosteroid doses should not be attenuated. 
Neurokinin-1 receptor  antagonists-   
 Aprepitant is the new antiemetic agent which has dramatically affected the control of CINV . 
Aprepitant is the most widely studied and the most commonly used drug of all the NK1 receptor 
antagonists77. Aprepitant has been shown to inhibit both the acute and delayed emesis induced by 
cytotoxic chemotherapeutic such as cisplatin by blocking substance P landing on receptors in the 
neurons. It was first approved by the FDA in 2003 as an oral antiemetic drug. Aprepitant has an 
average bioavailability of 60-65% when consumed orally, with 95% of the drug being bound to 
plasma proteins. Its peak plasma concentration is achieved about 4 hours after administration and 
is mainly eliminated from body by phase I metabolism. Invitro studies using human liver 
microsomes indicate that aprepitant is metabolized primarily by CYP3A4 with minor 
metabolism by CYP1A2 and CYP2C19. The half-life ranged from approximately 9 to 13 hours. 
No dose adjustment is needed in renal disease or mild to moderate hepatic insufficiency (Child-
Pugh score 5-9)77. 
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 Aprepitant is available commercially as capsules in bottles or blister pack. It is given for 
3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The 
recommended dose of Aprepitant is 125 mg orally 1 hour prior to chemotherapy treatment (Day 
1) and 80 mg once daily in the morning on Days 2 and 3. Capsules can be stored at 20-25°C. 
Most of the aprepitant studies have been conducted in adult patients(10-15). A pilot, single-
institution, randomized, double-blind, placebo-controlled trial by Herrington, et al.78 found that 
in patients who were receiving palonosetron, aprepitant, and dexamethasone for highly 
emetogenic chemotherapy, a single dose of aprepitant displayed similar effectiveness compared 
with 3-day aprepitant. Only a few adolescent studies are available. A clinical regimen tried 
effectively in adolescents by Gore, et al.79 is one of the studies which was done to clarify the 
efficacy and safety of aprepitant in adolescents. Pediatric studies are required to establish the role 
of this drug in management of CINV. The main reported side effects of aprepitant are 
constipation, fatigue and diarrhea. In view of its induction ofvarious enzymes, there is a 
possibility of drug interactions.. 
Fosaprepitant 
It  is  an  intravenous alternative to the current oral formulation for aprepitant.It  will  be mainly  
useful  in   patients  who  cannot  tolerate orally administered medications due to active 
mucositis, difficulty in swallowing, or poor function of the GI tract may require intravenous 
antiemetics prior to chemotherapy.80 Intravenous dexamethasone and intravenous 5-HT3 
receptor antagonists are available, but only an oral form of aprepitant was available till now. 
Fosaprepitant  would allow more convenient dosing in some clinical settings while maintaining 
efficacy and overall therapeutic margins. 
Fosaprepitant dimeglumine (MK-0517 or L- 758,298), a prodrug of aprepitant, was developed to 
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provide a parenteral alternative to the orally administered aprepitant 81,82   Fosaprepitant is 
rapidly converted to aprepitant via the action of ubiquitous phosphatases. Based on equivalence 
studies, 115 mg fosaprepitant seems to be the substitute for 125 mg orally administrated 
aprepitant. Tolerability of the prodrug is no different from the active drug. In phase I and II 
trials, fosaprepitant shows efficacy, but most of the large randomized efficacy studies have 
utilized aprepitant. Fosaprepitant has recently been approved by FDA and EMEA as an 
intravenous substitute for oral aprepitant on day 1 of the standard 3-day CINV prevention 
regimen, which also includes dexamethasone and a 5-HT3 antagonist. Side effects are similar to 
aprepitant with the addition of mild venous irritation and headache. 
 The tolerability of fosaprepitant has been evaluated in clinical trials with approximately 
150 patients 83,84. In these studies, fosaprepitant was given as a single intravenous dose (0.2 – 
200 mg), infused over 15 – 30 min, reconstituted in saline or polysorbate 80 to concentrations 
ranging from 1 to 25 mg/ml. Fosaprepitant has also been administered in single daily doses (25 – 
100 mg) on four consecutive days. The studies showed acceptable venous tolerability at 1 mg/ml, 
infused over 15 – 30 min, but a concentration of 25 mg/ml at doses of 50 mg and 100 mg, 
infused over 30 sec, was associated with venous irritation. Based on these studies, the incidence 
of venous irritation depends on the total dose, the concentration, and the rate of infusion 85. 
During the development of aprepitant, certain studies that assessed the tolerability of 
fosaprepitant also evaluated its efficacy in patients receiving chemotherapy. In a comparison of 
fosaprepitant versus ondansetron, each given as monotherapy prior to cisplatin, fosaprepitant was 
active against cisplatin-induced emesis, in particular in the delayed phase 83 Moreover, an 
additional trial demonstrated the tolerability and efficacy of fosaprepitant as part of combination 
therapy with dexamethasone 84. The clinical profile of fosaprepitant in these early studies 
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suggested that fosaprepitant could be appropriate as an intravenous alternative to the aprepitant 
oral capsule. 
In a study in healthy subjects, fosaprepitant was well tolerated up to 150 mg (1 mg/ml), and 
fosaprepitant 115 mg was AUC bioequivalent to aprepitant 125 mg 85. Fosaprepitant in the 
intravenous dose of 115 mg has been recently approved (February, 2008) by the FDA and the 
European Union (January, 2008) as an alternative to oral aprepitant 125 mg on day 1 of a 3-day 
regimen, with oral aprepitant 80 mg administered on days 2 and 3. Further studies are in progress 
to determine the efficacy, safety, and tolerability of a single dose of intravenous fosaprepitant 
necessary to replace the three-day oral regimen 86. 
Casopitant 
Casopitant is a novel substituted piperazine derivative, which has potential for the treatment of 
conditions mediated by tachykinins, including substance P and other neurokinins. Casopitant 
competitively binds to the NK-1 receptor, thereby inhibiting NK-1 receptor binding of substance 
P and blocking the activity of the receptor 87. Casopitant and its mesylate salt are being 
developed for the potential treatment of CINV, postoperative nausea and vomiting (PONV), 
anxiety, depression, and insomnia. Phase II and Phase III clinical trials have been completed for 
CINV 88,89.90,91 and Post operative nausea and vomiting 92, Two Phase III clinical trials with 
intravenous and oral casopitant have been completed. The first was designed to demonstrate that 
casopitant, when used in addition to dexamethasone  plus ondansetron, is more effective in the 
prevention of vomiting than dexamethasone and ondansetron alone in patients with solid 
malignant tumors receiving cisplatin- based highly emetogenic chemotherapy 91.  In the first 120 
hours of the first treatment cycle, complete responses were observed in 86% of patients in the 
oral casopitant (150 mg) group, compared with 66% for controls (p < 0.0001) and, in the first 24 
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hours complete response rates were 95% and 88% for the 150 mg oral casopitant and control 
groups, respectively (p = 0.0044). No vomiting occurred in 89% of patients and no significant 
nausea (NSN), as defined by the study, occurred in 78% of patients in the 150 mg oral casopitant 
group, compared with 68% (p < 0.0001) and 69% (p = 0.0272) for the control  group, 
respectively. In treatment cycles two to six, the complete response rates were 94, 92, 93, 91 and 
100%, respectively, in the casopitant treatment group, compared with 77, 78, 74, 97 and 56%, 
respectively, for the control group.  
The second of these Phase III clinical trials was designed to establish whether casopitant, 
when used in addition to dexamethasone plus ondansetron, is more effective in the prevention of 
vomiting than dexamethasone and ondansetron  alone in patients receiving non-cisplatin-based 
moderately emetogenic chemotherapy 90. The enrollment was 1933 patients with solid malignant 
tumors, mostly breast cancer (96%) with the primary endpoint again being complete 
response in the first 120 h post chemotherapy. Patients received oral casopitant in a schedule of 
oral casopitant (150 mg on day 1 and 50 mg/day on days 2 and 3); intravenous casopitant (90 
mg) on day 1, followed by 2 days of oral casopitant (50 mg/day); or oral casopitant (150 mg) on 
day 1. Treatment was continued for up to four cycles. Patients also received oral ondansetron (8 
mg BID on days 1 – 3) and intravenous dexamethasone (8 mg on day 1). In the first 120 h of the 
first treatment cycle for the intravenous/oral casopitant dose group, the complete response rate 
was 74% compared with 59% for controls (p < 0.0001). In the first 24 h, the complete response 
rate was 86% compared with 85% for controls (p = 0.585). There was no vomiting over 120 h in 
78 and 63% of patients for the casopitant and control groups, respectively (p < 0.0001). In 
treatment cycles two to four, complete responses were achieved in 81, 80, and 84% of patients in 
the intravenous/oral casopitant dose group compared with 63, 67, and 69% in the control group, 
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respectively. In the single oral casopitant dose group and the three oral casopitant dose groups, 
complete responses were observed in 73 and 73% of patients (p < 0.0001), respectively, over the 
first 120 h of the first treatment cycle, and in 88% (p = 0.1586) and 89% (p = 0.0545) of patients 
in the first 24 h. No vomiting occurred in 80 and 81% of patients (p < 0.0001) in these two dose 
groups, respectively. In treatment cycles two to four, complete responses were achieved in 80, 
79, and 82% of patients in the single oral casopitant dose group and in 81, 80, and 84% of 
patients in the three oral casopitant dose group, respectively. 
 A third Phase III clinical trial has been initiated to establish the efficacy of a single 
intravenous dose of casopitant, administered in combination with ondansetron and dexam-
ethasone, in preventing CINV in 700 patients with colorectal cancer receiving the moderately 
emetogenic chemotherapy oxaliplatin. The primary endpoint of this trial is the measurement of 
vomiting and the use of rescue medication during cycle 1 .93 
Olanzapine 
Olanzapine is an FDA-approved antipsychotic that blocks multiple neurotransmitters: dopamine 
at D1, D2, D3, D4 brain receptors, serotonin at 5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, 
catecholamines at alpha1 adrenergic receptors, acetylcholine at muscarinic receptors, and 
histamine at H1 receptors 94,95. Common side effects are sedation and weight gain 96,97, as well as 
an association with the onset of diabetes mellitus 98. Olanzapine’s activity at multiple receptors, 
particularly at the D2 and 5-HT3 receptors, which appear to be involved in nausea and emesis, 
suggests that it may have significant anti-emetic properties. 
A Phase I study demonstrated that olanzapine could be safely used for the prevention of 
delayed emesis in cancer patients receiving their first cycle of chemotherapy consisting 
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of cyclophosphamide, doxorubicin, cisplatin and/or irinotecan 99. Using the maximum tolerated 
dose of olanzapine in the Phase I trial, a Phase II trial was performed for the prevention of CINV 
in patients receiving their first course of either highly emetogenic or moderately emetogenic 
chemotherapy. When olanzapine was added to granisetron and dexamethasone in the acute 
period, and added to dexamethasone  in the delayed period, there was a very high complete 
response (no emesis, no rescue) and excellent  control of nausea. The study concluded that 
olanzapine is safe and highly effective in controlling acute and delayed CINV in patients 
receiving highly emetogenic and moderately emetogenic chemotherapy 100. 
An additional Phase II study was performed to determine the control of acute and delayed 
CINV in patients receiving moderately emetogenic chemotherapy and highly emetogenic 
chemotherapy with the combined use of palonosetron and olanzapine, and dexamethasone with 
the dexamethasone given on day one only. On day 1 of chemotherapy, 40 chemotherapy- 
naïve patients received an anti-emetic regimen consisting of dexamethasone, palonosetron, and 
olanzapine. Patients continued olanzapine for days 2 – 4 following chemotherapy 
administration. Patients recorded daily episodes of emesis, utilizing the MD Anderson Symptom 
Inventory, and the utilization of rescue therapy. For the first cycle of chemotherapy, the complete 
response (no emesis, no rescue) for the acute period (24 h postchemotherapy) was 100%, the 
delayed period (days 2 – 5 postchemotherapy) 75%, and the overall period (0 – 120 h 
postchemotherapy) 75% in 8 patients receiving highly emetogenic chemotherapy  and was 97%, 
75%, and 72% in 32 patients receiving moderately emetogenic chemotherapy. No nausea for 
patients in the acute period was 100%, the delayed period 50%,  and the overall period 50% in 8 
patients receiving  highly emetogenic chemotherapy and was 100%, 78%, and 78% in 32 patients 
receiving moderately emetogenic chemotherapy. The complete response and control of nausea in 
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subsequent cycles of chemotherapy were not significantly different from cycle one. Olanzapine 
combined with a single dose of dexamethasone and a single dose of palonosetron was very 
effective in controlling acute and delayed CINV in patients receiving both highly and moderately 
emetogenic chemotherapy 101. 
Gabapentin 
A recent report by Guttuso et al. 102 in a small number of patients receiving adjuvant 
chemotherapy (doxorubicin, cyclophosphamide) for breast cancer suggested that the 
anticonvulsant gabapentin might reduce delayed nausea. Further studies will be necessary to 
determine the efficacy of this agent. 
 Cannabinoids 
Two oral formulations of cannabinoids, dronabinol and nabilone, have been approved by the 
FDA for use in  CINV refractory to conventional antiemetic therapy 103 The National 
Comprehensive Cancer Network has suggested the use of cannabinoids for breakthrough 
treatment 104. Cannabinoid receptors of the CB1 type are present in the area postrema, NTS, and 
dorsal motor nucleus which are key sites within the brainstem for emetogenic control 105. Recent 
evidence suggests that cannabinoid CB2 receptors are present on brainstem neurons and may 
have a role in mediating the cannabinoids effects on emesis 105,106. 
There have been no comparative studies of dronabinol and nabilone with the 5-HT3 receptor 
antagonists and the NK-1 receptor antagonists in the prevention of CINV. The role of the 
cannabinoids in the prevention of CINV remains to be established 103. 
Anti-emetic  prophylaxis – 
Chemotherapy used in the treatment of most nonhematologic and some hematologic cancers is 
most  frequently administered intravenously over the course of a single day. This is also the 
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setting in  which clinical data on the use of antiemetic agents are most abundant. The 
fundamental principle that  should guide decisions about antiemetic treatment is that complete 
prevention of nausea and vomiting is the ultimate objective, and it is best accomplished with the 
use of appropriate, evidence-based  preventive treatment. The choice of regimen is guided by 
two considerations: the emetogenic potential  of the chemotherapy and whether there is a 
substantial risk of delayed nausea and vomiting. 
Anti-emetic prophylaxis in highly emetogenic chemotherapy(HEC) – The anti-emetic 
regimen of choice in this setting is a combination of aprepitant,  5HT3 receptor antagonist and 
dexamethasone. Abundant clinical data support this combination for patients receiving cisplatin-
based chemotherapy. Hesketh et al showed in their study that compared with standard dual 
therapy , addition of aprepitant was generally well tolerated and provided consistently superior 
protection against CINV in patients receiving highly emetogenic chemotherapy.107.Warr et al 
showed in their study that aprepitant arm in comparison to the standard dual therapy arm had a 
statistically significant less nausea, better control of acute and delayed emesis and also lower 
frequency of the intake of rescue medications .108.Similarly Poli-Bigelli study which was a latin 
American study showed that addition of aprepitant to the standard anti-emetic therapy 
significantly improves the control of CINV.109.Chawla et al in their study also confirmed the 
superiority of the addition of aprepitant to the standard antiemetic arm.110.Thus based on the 
available data addition of aprepitant to the  standard antiemetic regimen results in significant 
improvement in the control of acute emesis, delayed emesis, nausea and also has a better quality 
of life . 
Palonosetron has also  been approved for the prevention of acute CINV in patients receiving 
either moderately or highly  emetogenic chemotherapy and for the prevention of delayed CINV 
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in patients receiving moderately emetogenic chemotherapy. In recent studies, compared to the 
first-generation 5-HT3 receptor antagonists, palonosetron in combination with dexamethasone 
demonstrated better control of delayed CINV in patients receiving highly emetogenic 
chemotherapy. 
Grunberg et al in their study of 667 patients receiving highly emetogenic Chemotherapy  (HEC) 
(cisplatin, 60 mg/m2) compared one of two doses of palonosetron (0.25 mg or 0.75 mg) 
or ondansetron (32 mg) pre-chemotherapy. Sixty-seven percent of the patients in all three study 
arms also received  dexamethasone. Single-dose palonosetron was as effective as ondansetron in 
preventing acute CINV and with dexamethasone pretreatment, its effectiveness was significantly 
increased over ondansetron throughout the 5-day post chemotherapy period.64. 
Hajdenberg et al111 reported the results of another multicenter, open-label study evaluating the 
use of palonosetron (0.25 mg) and dexamethasone (8 mg) prior to patients receiving moderately 
to highly emetogenic chemotherapy  .A CR was observed in 84% of patients in the first 24 hours 
post-chemotherapy (acute), 59% of patients during days 2 to 5 (delayed), and 59% days 1 to 5 
(overall period). No nausea was observed in 78% of patients in the acute period, and 50% in the 
overall period. No significant adverse events were reported in the study. Saito et al112 conducted 
a double-blind, double-dummy, randomized, comparative phase III trial in 1143 patients 
receiving HEC  (cisplatin or the combination of an anthracycline and cyclophosphamide). Of 555 
patients in the palonosetron group, 418 (75.3%) had a complete response during the first 24 
hours (acute period) compared with 410 of 559 patients (73.3%) in the granisetron group. During 
the delayed period, 315 of 555 patients (56.8%) had a complete response in the palonosetron 
group compared with 249 of 559 patients (44.5%) in the granisetron group (P< 0.0001). When 
administered with dexamethasone, palonosetron  prevented CINV which was non-inferior to 
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granisetron in the acute period and better than granisetron in the delayed period, with a 
comparable safety profile for the two treatments. Thus palonosetron is effective in the control of 
CINV both acute and delayed and also has a modest improvement in the quality of life of 
patients receiving highly emetogenic chemotherapy. Even though palonosetron is proved 
superior to other first generation 5HT3 receptor antagonists , the guidelines do not mention the 
use of any particular 5HT3receptor antagonist in combining with dexamethasone and aprepitant.  
Anti- emetic prophylaxis in Moderately emetogenic chemotherapy- 
As compared to the scenario in the HEC group ,the  choice of use of anti-emetic prophylaxis in 
the MEC group is relatively controversial. Conventionally dexamethasone and 5HT3receptor 
antagonists in combination were the agents of choice .The role of aprepitant in the control of 
emesis in the MEC is becoming more clear and strong .A study by Warr et al was one of the first 
studies to define the role of the aprepitant in the control of emesis in patients receiving 
moderately emetogenic chemotherapy. This study showed that aprepitant arm had a better 
control of CINV as compared to the standard arm.113  A Chinese study also was done which 
compared addition of aprepitant to the standard anti emetic regimen and showed that addition of 
aprepitant is beneficial.114. 
Various studies for palonosetron are reported which have showed efficacy of 
palonosetron over other first generation 5HT3receptor antagonists. Gralla et al 63 showed that a  
single intravenous dose of palonosetron 0.25 mg was significantly superior to intravenous 
ondansetron 32 mg in the prevention of acute and delayed CINV in patients receiving MEC116. 
Eisenberg et al 62 in their study showed that single dose of  palonosetron was superior to 
granisetron  in patients receiving  MEC . Thus based on the above mentioned studies and many 
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more phase II studies , palonosetron  has been found to be superior to first generation 
5HT3receptor antagonists in the management of patients receiving MEC. 
According to the update on antiemetic guidelines in 2007 by Karin Jordan 115 which 
included the  Multinational Association of Supportive Care in Cancer (MASCC) antiemetic 
guidelines , NCCN guidelines for anti emetics and ASCO guidelines   recommended  the 
combination of a 5-HT3RA plus dexamethasone with or without aprepitant for acute CINV with 
moderately emetogenic chemotherapy. However, the key question in this setting is whether 
aprepitant should be part of the antiemetic prophylaxis. The ASCO and MASCC guidelines 
recommend the triple combination (a 5-HT3RA, dexamethasone, and aprepitant) for patients 
receiving the combination of an anthracycline and cyclophosphamide– based regimen. The 
NCCN guidelines, however, broaden the spectrum of the use of aprepitant in this setting and 
advise use in selected patients receiving other chemotherapies of moderately emetogenic risk 
(e.g., carboplatin, epirubicin, ifosfamide, irinotecan). Dexamethasone is the preferred agent to 
use for delayedCINV with moderately emetogenic chemotherapy. Nonetheless, when aprepitant 
is used for the prevention of acute CINV then it should also be used for the prophylaxis of 
delayed CINV as monotherapy, as stated by the MASCC and ASCO guidelines. As discussed 
before, the NCCN guidelines suggest aprepitant with or without dexamethasone in this situation. 
A 5-HT3RA can be used as an alternative, although their therapeutic role in the delayed phase is 
rather limited 116. In contrast to all three previously published guidelines, metoclopramide is not 
reflected in the new guidelines as an alternative option. 
Low Emetogenic Chemotherapy 
The MASCC and ASCO guidelines unanimously recommend the use of a steroid alone in the 
first 24 hours and no prophylaxis beyond 24 hours for acute CINV with low emetogenic 
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chemotherapy. The NCCN guidelines recommend prochlorperazine or metoclopramide as well, 
as alternative drugs to dexamethasone. 
 
Minimally Emetogenic Chemotherapy 
All three guidelines suggest that, for patients treated with agents of low emetic risk, no 
antiemetic drug should be routinely administered before chemotherapy. 
 
MANAGEMENT OF BREAKTHROUGH AND REFRACTORY CINV 
Breakthrough CINV is defined as an event that happens in spite of optimal preventive treatment. 
Refractory CINV is CINV that recurs in subsequent cycles of therapy when all previous 
preventive and rescue treatments fail. If optimal treatment has been given as prophylaxis, 
repeated dosing of the same agents is unlikely to be successful the addition of dopamine-receptor 
antagonists (metoclopramide) might be useful, or adding other 
agents such as benzodiazepines or neuroleptics. Olanzapine, an atypical neuroleptic, could also 
be considered, as suggested by the MASCC and NCCN guidelines.  
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METHODS AND MATERIALS 
Newly diagnosed patients of breast carcinoma receiving the first cycle of moderately emetogenic 
chemotherapy were included in the study. 
 Inclusion criteria- 
¾ Patients with carcinoma breast confirmed histopathologically /cytologically  
¾ Age more than 18 years 
¾ Patients receiving their first cycle of chemotherapy 
¾ Patients should be receiving moderately emetogenic chemotherapy as per the Heskeths 
classification – combination of anthracycline and cyclophosphamide, anthracyclines 
alone, Cyclophosphamide alone with a dose of 750mg/m2 to  1.5 gm/m2, any 
combination containing anthracyclines and cyclophosphamide (dose of less than 1.5 
gm/m2) 
¾ Patients with predicted life expectancy of more than or equal to 4 months  
¾ Patients with karnofsky score of more than or equal to 60   
Exclusion criteria- 
¾ Patients with CNS metastases  
¾ Patients who had vomited in the 24 hours before the expected date of 
chemotherapy 
¾ Patients taking corticosteroids (any dose ) for any other causes like bronchial 
asthma etc 
¾ Patients who have received radiation to abdomen or pelvis in the week before the 
chemotherapy date 
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¾ Patients having active infection, a systemic fungal  infection  
¾ Patients with abnormal renal function (> 1.5 times the normal value ) 
¾ Patients with abnormal LFT (Total bilirubin->1.5 times the normal) 
¾ Patients with elevated liver enzymes (>1.5 times the normal ) 
¾ Patients with abnormal hemogram(WBC count<3000),Absolute neutrophil cont 
<1500, platelet count <1lakh 
¾ Patients who have taken any anti emetic within 48 hrs prior to chemotherapy 
 
The 150  patients who were eligible to be included in the study, after taking informed consent 
were randomly assorted to one of the three arms of prophylactic anti emetic therapy. 
Ondansetron arm -Patients received 8mg of intravenous ondansetron and 8mg of intravenous 
dexamethasone prior to chemotherapy followed by 8mg of oral ondansetron 8 hrs after 
chemotherapy followed by 8mg of oral ondansetron twice daily on day2 and day3. 
 
Palonosetron arm  -Patients received 0.25mg of intravenous palonosetron 30 minutes prior to 
chemotherapy.8 mg of intravenous dexamethasone to be administered as premedication prior to 
chemotherapy. No drugs on day2 and day3. 
 
Aprepitant arm –Patients on day1 received 125 mg of oral aprepitant 1 hour prior to 
chemotherapy followed by 8mg of intravenous ondansetron and 4mg of intravenous 
dexamethasone prior to chemotherapy followed by 8 mg of oral ondansetron 8 hrs after 
chemotherapy. Patients received 80 mg of aprepitant on days 2 and 3. 
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Patients were allowed rescue medications during any time in the study period if they had emesis 
or severe nausea even in the absence of emesis. Domperidone, ondansetron, phenothiazines, 
butryophenones and benzodiazepines were allowed as rescue medication. 
 Patients were given a printed sheet of paper which had 5 columns for the 5 days after 
chemotherapy and patients were also given the FLIE questionnaire in their local language on 
Day 1 and were explained clearly in their local language that they will be required to fill the 
questionnaire on day 6. Patients also were clearly instructed to note down the emetic episodes if 
at all they had emesis. They were asked to note the date of emesis, time of emesis, number of 
emetic episodes and rescue medication details like what rescue medication and for how many 
days they have taken the same. On Day 6 patients were again assessed and were asked to fill the 
FLIE questionnaire.  
 FLIE questionnaire has 2 domains – nausea domain and vomiting domain. Each domain 
has 9 questions. Patient has to mark her/his responses on a visual analogue scale which is marked 
from 1 to 7 dividing the scale into 6 equal parts. If the nausea/vomiting has affected the 
individual to the maximum then they have to mark 1 and If they are not at all affected by nausea 
or vomiting then they have to mark 7 and in between markings denote the intensity of affection 
as per the score. So score of 6 and above for a question is taken as the patient has not been 
affected by nausea/vomiting. 9 questions are there in each domain and a score of >54 in that 
domain means that the patient is having excellent quality of life and is not affected by CINV. 
FLIE scores are taken individually for domains and then added with a score of >108 suggesting 
excellent quality of life 
Complete response (CR) was defined as no emesis or no intake of rescue medications during a 
period of 120 hours after the initiation of chemotherapy. 
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Acute CR was defined as no vomiting episodes and no intake of rescue medications during the 
first 24 hours after chemotherapy. 
Delayed CR was defined as no vomiting episodes and no intake of rescue medications after 24 
hours after chemotherapy up to 120 hours. 
Moderately emetogenic chemotherapy was defined as per the Heskeths classification of 
chemotherapeutic agents. It was defined as risk of emesis of 31-90% following the 
administration of chemotherapy in the absence of antiemetic prophylaxis. combination of 
anthracycline and cyclophosphamide, anthracyclines alone, Cyclophosphamide alone with a dose 
of 750mg/m2 to  1.5 gm/m2, any combination containing anthracyclines and cyclophosphamide 
(dose of less than 1.5 gm/m2). 
Chi-square test, Mantel-haenszel and Yates corrected were the statistical methods which were 
used to calculate the significance of the results. 
Institute protocol for the treatment of breast cancer- 
Early breast cancer – upfront surgery followed by adjuvant chemotherapy with or without 
radiotherapy followed by hormonal manipulation in appropriate settings 
Locally advanced breast cancer – neo- adjuvant chemotherapy 2-3 cycles of 600mg/m2 
5fluorouracil+ 60mg/m2 of epirubicin + 600 mg/m2 of cyclophoshamide or 175 mg/m2 
paclitaxel + 60 mg/m2 of epirubicin with 40 Gy radiotherapy to breast, axilla with or without 
supra clavicular area followed by modified radical mastectomy followed by completion of 
chemotherapy and then hormonal manipulation appropriately. Radiotherapy to internal 
mammary region also is given to appropriate patients. 
Metastatic breast carcinoma – Chemotherapy , bisphoponates whenever indicated, palliative 
radiotherapy wherever indicated. 
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RESULTS 
DEMOGRAPHIC PROFILE 
150 patients of breast cancer receiving moderately emetogenic chemotherapy were included in 
the study with 50 each receiving ondansetron or palonosetron or aprepitant as the antiemetic 
prophylaxis. 
Age distribution – The median age in the ondansetron arm was 46, in the palonosetron arm was 
45 and 51 in the aprepitant arm. 
Tab-1 – age distribution 
 Median age Min age Max age 
Ondansetron 46 27 65 
palonosetron 45 34 61 
Aprepitant 51 33 65 
                                                                                                                 
Breast cancer patients in neo-adjuvant, adjuvant and metastatic settings were all included with 
the patients being equally distributed in all the three arms .Ondansetron arm had 60% of patients 
in neoadjuvant setting with 78% in palonosetron arm and 70% in aprepitant arm. 30% of patients 
in ondansetron arm were in adjuvant setting with palonosetron having 14% and aprepitant having 
18% in adjuvant setting. Patients with metastatic breast cancer were also equally distributed in 
each arm with 10%, 8% and 12% respectively in ondansetron, palonosetron and aprepitant arms.  
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Fig – 3 – distribution of the patients in various settings in the three arms  
     Number of patients in each arm receiving radiation to the chest wall was almost similar with 
32% in ondansetron arm, 34% in palonosetron arm and 33% in aprepitant arm respectively. 
 
 
Fig 4- distribution of patients in each arm receiving radiation 
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 Patients in all three arms were fairly matched with respect to the other variables like co morbid 
conditions, ER, PR and HER-2 neu receptor status.  
Tab 2- Variables in the three arms 
 Ondansetron Palonosetron Aprepitant P- value 
Hypertension 27% 35% 37% 0.6272 
Diabetes Mel  32 25 43 0.04 
IHD 2 2 0 0.6024 
ER  31 31 36 0.4205 
PR 33 34 33 0.9733 
HER 2neu 31 36 32 0.8029 
 
Outcomes-Responses in each of the arms were anlysed and complete response in acute phase, 
delayed phase and for a total duration of 120 hours after chemotherapy were obtained. 
Throughout the study population 20% had acute emesis and 31% had delayed emesis. 
Fig-5- Acute and delayed emesis percentages across the study population 
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 So 36%, 18% and 06% in the ondansetron, palonosetron and aprepitant arms respectively had 
acute emesis. 62%, 24% and 08% of patients in ondansetron, palonosetron and aprepitant arms 
respectively had delayed emesis. 
Fig 6- Acute emesis and delayed emesis in each arm 
 
 
Fig7- Acute emesis progressing to delayed emesis 
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 83.3% in the ondansetron arm, 44.4% in the palonosetron arm and 33.3% in the aprepitant arm 
with acute emesis continued to have delayed emesis.   
 
Fig 8- Complete response rates in acute, delayed and total phase 
 
 
 
 
 
     Complete responses were much better in the aprepitant and palonosetron arms as compared to 
the control ondansetron arm 64%, 82% and 94% were the acute phase CR rates in ondansetron, 
palonosetron and aprepitant arms which were statistically significant (p-0.0008). 
Similarly delayed phase CR rates of 38%, 76%, 92% and total CR rates of 32%, 66% and 88% 
were obtained in ondansetron, palonosetron and aprepitant arms respectively 
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Fig 9- Functional living index – emesis score rates 
 
 
As seen in the Figure 7 and table3 the functional living index- emesis (FLIE) scores were better 
in the aprepitant and palonosetron arms as compared to the ondansetron arms. 
 
Table 3-FLIE scores among the three arms 
 FLIE-NAUSEA 
Score>54 
FLIE- VOMITING 
Score>54 
FLIE-TOTAL 
Score>108 
Ondansetron 8% 34% 16% 
Palonosetron  34% 72% 40% 
Aprepitant  46% 90% 52% 
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Number of patients taking rescue medications was also less in the palonosetron and aprepitant 
arms 64% and 86% respectively. 
Table – 4 Comparison of the three drugs with respect to the use of rescue medications 
  Number of patients taking rescue medications  
Ondansetron  68% 
Palonosetron  36% 
Aprepitant  14% 
  
Palonosetron when compared to ondansetron had a significantly favourable outcome with respect 
to the control of CINV. 
Fig10- Comparison of CR rates in ondansetron and palonosetron arms 
 
The acute phase CR rate in ondansetron arm was 64% as compared to 82% in the palonosetron 
arm which was statistically significant (p- 0.04 as per the Mantel-Haenszel method). 
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The difference between the two arms was much more evident in delayed phase CR rates of 38% 
in ondansetron arm as compared to the 76% in the palonosetron arm with a p value of 
0.0001(Yates corrected method and mantel- Haenszel methods). 
The CR rates over the total period of 120 hours which was the total CR rate was also 
significantly high in palonosetron arm with a value of 66% as compare to 32% in the 
ondansetron arm (p- 0.001-Yates corrected method) 
 
Fig 11- comparison of FLIE scores between the ondansetron and palonosetron arms 
 
 
 
 
Palonosetron also was significantly better with respect to the FLIE scores for nausea , vomiting 
and the total FLIE score .8% in ondansetron arm had FLIE nausea score of >54 as compared to 
34% in the palonosetron arm. The scores in FLIE vomiting domain were 34% and 72% 
respectively for ondansetron and palonosetron arms with a statistically significant  p value of 
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0.003 (Yates corrected method. The total FLIE score of >108 was seen in 16% in ondansetron 
arm as compared to 40% in palonosetron arm (p-0.014 by Yates corrected method) 
32% of patients in ondansetron arm did not use rescue medication as compared to 64% in the 
palonosetron arm which again was a statistically significant difference (p- 0.002 by Yates 
corrected method) 
Fig 12- Comparison of the Rescue medication usage between ondansetron and palonosetron arms 
 
 
 
Thus palonosetron in comparison to the conventional anti- emetic ondansetron fared better with 
respect to the control of emesis in acute phase, delayed phase and combined acute and delayed 
phases. Palonosetron also had significantly favourable outcome with respect to FLIE scores in 
both nausea and vomiting domains and also the total FLIE score. 
Palonosetron was then compared to aprepitant and the acute phase CR rates 82% in palonosetron 
arm as compared to 94% in aprepitant arm which was not statistically significant ( p- 0.12 Yates 
corrected method).Aprepitant  fared better than palonosetron in delayed phase control, total CR, 
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FLIE score in vomiting domain  and with respect to rescue medication usage .76% achieved 
delayed phase CR in palonosetron arm as compared to 92% in aprepitant arm which was 
statistically significant with a p value 0.02.Total CR was achieved in 66% of patients in the 
palonosetron arm as compared to 88% in aprepitant arm which was statistically significant , p- 
0.01 as per the Yates corrected method. 
 
Fig 13 – Comparison of Aprepitant and Palonosetron 
 
 
 
34% in Palonosetron arm achieved a FLIE score of >54 in nausea domain as compared to 46% in 
aprepitant arm which was not statistically significant, p- 0.30 
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Fig14- comparison of Aprepitant and Palonosetron for FLIE scores 
 
In vomiting domain aprepitant arm had significantly better results with 90% achieving a score of 
>54 as compared to 72% in palonosetron arm (p-0.04).FLIE total score of >108 was achieved by 
40% in palonosetron arm as compared to 52% in aprepitant arm, p-0.31.In aprepitant arm 86% 
did not use rescue medications as compared to the 64% in the palonosetron arm, p- 0.02. 
Aprepitant was much superior to ondansetron in all the parameters with CR rates of 94% in acute 
phase, 92% for delayed phase, 88% both acute and delayed phase combined as compared to 
64%, 38% and 32% respectively in the ondansetron arm. 
 
Table-5 Comparison of Ondansetron and Aprepitant 
 Acute 
CR 
Delayed 
CR 
Total CR FLIE-N 
>54 
FLIE-V 
>54 
FLIE-T 
>108 
Rescue 
med used 
Aprepitant 94% 92% 88% 46% 90% 52% 68% 
Ondansetron 64% 38% 32% 08% 34% 16% 14% 
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As shown in the above table aprepitant fared much better than ondansetron arm with FLIE scores 
of 46% in nausea domain, 90% in vomiting domain and 52% in the combined domain as 
compared to the respective scores of 08%, 34% and 16% in the ondansetron arm.68% in the 
aprepitant arm did not use rescue medications as compared to 14% in the ondansetron arm .All 
the values were statistically significant. 
Aprepitant fared much better than the conventional ondansetron and also palonosetron. Subset 
analysis comparing the efficacy of palonosetron and aprepitant in patients less than 50 years and 
more than 50 years was done.   
 
Table 6- Comparison of Palonosetron and Aprepitant in age <50 years 
 
 Acute 
CR 
Del CR Total CR FLIE-N 
Score>54 
FLIE-V 
Score>54 
FLIE-T 
Score>108 
Res med 
not taken 
Aprepitant 90% 95% 90% 55% 95% 55% 90% 
Palonosetron 86% 72.2% 63.8% 33.3% 69.4% 38.8% 61.1% 
P value 0.67 NS 0.03 0.03 0.19 NS 0.02 0.37 NS 0.04 
   
So as can be observed from the above table, in patients less than 50 years, aprepitant fared better 
than palonosetron in all the comparable response parameters with statistically  significant 
difference noted in delayed CR, total CR and FLIE-score in the vomiting domain with values  of 
95%,90% and 95% respectively in aprepitant arm as compared to 72.2%, 63.8% and 69.4% for 
the palonosetron arm.90% of the patients in aprepitant arm did  not take rescue medications as 
compared to 61.1% in the palonosetron arm.     
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Table 7- Comparison of Palonosetron and Aprepitant in age >50 years 
 Acute 
CR 
Del CR Total CR FLIE-N 
Score>54 
FLIE-V 
Score>54 
FLIE-T 
Score>108 
Res med 
not taken 
Aprepitant 96% 90% 86.6% 40% 86.6% 50% 83.3% 
Palonosetron 71% 85.5% 71.4% 35.7% 78.5% 44.4% 71.4% 
P value 0.02  Sig 0.67 0.24 0.95 0.66 0.90 0.29 
 
Interestingly in the patients >50 years the difference between aprepitant and palonosetron is 
negligible with only statistically significant outcome in the acute phase  CR rates of 96% in 
aprepitant arm as compared to 71% in the palonosetron arm. Delayed phase and Total CR rates 
were 90% and 86.6% respectively in aprepitant arms as compared to 85.5% and 71.4% in the 
palonosetron arm. The favourable FLIE scores in the nausea domain, vomiting domain and 
combined were seen in 35.7%, 78.5% and 38.8% respectively in palonosetron arm as compared 
to 40%, 86.6% and 44.4% in the aprepitant arm.61.1% in the palonosetron arm did not take 
rescue medications as compared to 71.4% in the aprepitant arm which was not statistically 
significant.  
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DISCUSSION 
 Anti emetic prophylaxis in patients receiving Highly emetogenic chemotherapy (HEC) is well 
standardized and clear but unfortunately very few studies are available in the literature 
evaluating the role of newer anti emetics in the prevention of CINV in patients receiving 
Moderately emetogenic chemotherapy (MEC).The scenario of anti emetic prophylaxis is also 
less clear regarding the optimum   anti emetic prophylaxis in MEC. The role of Aprepitant and 
Palonosetron to a certain extent is not yet clearly determined in MEC. Patients with breast cancer 
receiving a combination of anthracyclines and Cyclophosphamide have a peculiar problem. 
Female gender is a risk factor for development of CINV and coupled with the combination of 
drugs like anthracyclines with Cyclophosphamide the patients are more likely to develop CINV 
as compared to the subsets receiving other MEC. Hence a more potent anti-emetic regimen is 
likely required for these patients instead of the currently existing conventional anti emetics. 
            In our study we have compared the anti-emetic efficacies of the two newer drugs 
palonosetron and aprepitant to the conventional and a more time tested ondansetron. We have 
also compared palonosetron and aprepitant with respect to their ability to control acute emesis, 
delayed emesis, impact on the quality of life issues by the reduction of of nausea and vomiting 
and their ability to reduce the intake of rescue medications post chemotherapy.  
 The primary end point of our study was to assess the ability of the three anti emetic agents to 
achieve complete response defined as absence of vomiting and no intake of the rescue 
medications during a period of 120 hours post chemotherapy.    
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Fig 15- CR rates in Warr et al study 
 
 
Fig 16- CR rates in our study 
 
The total complete response rates were 32%, 66% and 88% for ondansetron, palonosetron and 
aprepitant arms respectively. Palonosetron had statistically significant total CR rates as compared 
to ondansetron (p-0.001) and in turn aprepitant had better total CR rates than palonosetron which 
was statistically significant in patients less than 50 yrs .David G Warr113 et al in their study of 
efficacy of aprepitant in patients with breast cancer receiving MEC showed that aprepitant arm 
had significant improvement in total CR rates 51% in aprepitant arm and 42% in the ondansetron 
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arm. Winnie Yeo et al 114 comparing the effect of addition of aprepitant to the standard 
antiemetic regimen in patients with breast cancer receiving MEC however failed to show any 
benefit for aprepitant in the CR rates of acute and delayed phases. The possible explanation may 
be that it had a small number (127patients) and a second point may be the difference in the 
ethnicity of the study populations between their study and study of Warr et al and ours.  Gralla et 
al 63 comparing the efficacy of palonosetron to ondansetron in prevention of CINV in patients 
receiving MEC had a total CR rate of 69.3% which was comparable to our study.Eisenberg 62et 
al also showed that palonosetron was better than ondansetron in patients receiving MEC. 
 Secondary end points in our study were to find out the efficacy of the three drugs in achieving 
CR in acute phase, CR in delayed phase, impact on quality of life based on the FLIE scores, in 
reducing the intake of rescue medications .94% in the aprepitant arm as compared to the 64% in 
ondansetron arm achieved CR in acute phase which was statistically significant and  Warr et al113 
in their study also had improved CR rates in acute phase with 76% in  aprepitant arm  versus 
69% in ondansetron arm. Acute phase CR rates with palonosetron arm was 82% which was  
almost similar to the Gralla et al 63study where the acute phase CR rate for palonosetron was 
81%. 
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Fig 17-Warr et al study 
 
 
 
Fig 18- Our study 
 
 
           In our study 20% of the total study population had acute emesis and delayed emesis was 
seen in 31% which was almost correlating with the Warr et 113 al study in which they studied the 
efficacy of aprepitant in patients receiving HEC, with acute emesis occurring in 20% and 
delayed emesis in 35% of the entire study population .In our study 83.3% of patients with acute 
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emesis continued to have delayed emesis in ondansetron arm compared to 44.4% in palonosetron 
arm and 33.3% in aprepitant arm. Emesis in acute phase is known to be associated with greater 
likelihood of emesis in the delayed phase which was again consistent in our study. The 
percentage of patients with acute emesis progressing to delayed emesis was significantly lower 
in the aprepitant arm as compared to other two arms with palonosetron faring better than 
ondansetron as mentioned above. However regardless of whether patients had acute emesis or 
not , the incidence of delayed emesis was consistently lower in the aprepitant arm  92% as 
compared to 78% in palonosetron arm and 38% in the ondansetron arm thus signifying the 
greater efficacy of aprepitant. In the warr 113 et al study the corresponding delayed phase CR 
rates were 55% in aprepitant arm and 49% in ondansetron arm. 
 In our study the delayed phase CR rate was 76% in the palonosetron arm which was again 
consistent with the delayed phase CR rate of 74.1% in the Gralla et al study. 
The  other secondary end points in our study were to determine the impact of the anti-emetic 
regimen on the quality of life based on the FLIE questionnaire .90% of patients in aprepitant arm 
had FLIE score of >54 in vomiting domain as compared to 72% in palonosetron arm and 34% in 
ondansetron arm. Warr 113 et al in their study had almost similar values for aprepitant arm which 
was 85.7% but the ondansetron arm also had a 71.8% with score of >54 which was higher than 
the ondansetron arm in our study which possibly could be explained by the increased number of 
patients in ondansetron arm achieving CR as compared to our ondansetron group.46% in the 
aprepitant arm could manage a FLIE score of >54 in nausea domain as compared to 34% in 
palonosetron and 08% in ondansetron arms which was inferior to the values of 53.5% and 50.5% 
for the aprepitant and ondansetron arms respectively in the Warr et al113study denoting that 
possibly patients in our study group had more nausea  which can be most probably attributed to 
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the poor nutrition and social status of majority of our patients.FLIE total scores of >108 was 
obtained by 52% of patients in aprepitant arm compared to 40% and 16% in palonosetron and 
ondansetron arms respectively which again was inferior to values of 63.5% and 55.6% in 
aprepitant and ondansetron arms of Warr et al study. 
 In patients receiving aprepitant 86% of patients did not take rescue medications as compared as 
compared to 64% in the palonosetron arm and 14% in the ondansetron arm .Winnie Yeo et al114 
in their study also showed that patients taking aprepitant had lesser incidence of intake of rescue 
medications. 
 Hence the primary and secondary outcomes denote that Aprepitant and Palonosetron are 
significantly better than ondansetron in the control of CINV in patients receiving MEC .The 
impact on quality of life in nausea domain is not affected by any of the three drugs but in the 
vomiting domain again palonosetron and aprepitant fare better than ondansetron. 
 There are no studies which have compared palonosetron head to head with aprepitant in patients 
receiving either HEC or MEC .Our study is notable and in fact is more relevant in a limited 
resource country like ours as majority of the patients will not be able to afford most of the 
medicines. So whether palonosetron is inferior to aprepitant or equal in efficacy to aprepitant 
will be an interesting question to answer. In our study even though on preliminary analysis 
aprepitant was superior to palonosetron but on subset analysis with the study population  
stratified into > 50 years and < 50 years , palonosetron fared almost non inferior to aprepitant in 
the more than 50 years age group. 
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Fig 19 – In patients < 50 years, comparison of aprepitant with palonosetron 
 
Aprepitant was superior to palonosetron in most of the parameters in patients aged < 50 years. 
Interestingly aprepitant was found to be almost similar in efficacy to palonosetron in patients 
aged > 50 years. 
Fig 20- In >50 years comparison of palonosetron and aprepitant 
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One possible explanation is younger females are at increased risk of CINV as compared to the 
older population , Hence whether palonosetron became non inferior to aprepitant in the elderly 
population because their overall risk  of developing CINV itself is low needs to be proved 
further. As the number of patients in our study group was small further studies with large 
numbers are required to prove or disprove the above mentioned observation.   
 In comparison to ondansetron, both palonosetron and aprepitant have statistically significant  
Antiemetic action in patients receiving MEC with better control of CINV in both acute and 
delayed phases  and with significant impact on the improvement of quality of life in vomiting 
domain in FLIE as compared to nausea domain. Aprepitant based antiemetic regimen is better 
than palonosetron regimen in patients receiving MEC with age less than 50 years but 
interestingly palonosetron is non inferior to aprepitant based regimen in patients aged more than 
50 years. 
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CONCLUSIONS 
 
1. Ondansetron based anti-emetic prophylaxis even in patients receiving moderately 
emetogenic chemotherapy is sub optimal 
2.  Palonosetron is superior to ondansetron in the prevention of CINV in patients 
receiving moderately emetogenic chemotherapy 
3.  Aprepitant is superior to both ondansetron and palonosetron in the prevention of 
CINV in patients receiving moderately emetogenic chemotherapy  
4.  In patients less than 50 years the superiority of aprepitant over palonosetron is more 
evident 
5.  In patients more than 50 years palonosetron is non inferior to aprepitant. 
6.  Nausea continues to be a persistent problem in spite of adequate control of emesis, as 
shown in the FLIE indices for nausea domain  
7.  Administration of aprepitant or palonosetron leads to decrease in the use of rescue 
medications  
8.  In places with limited resources palonosetron is an useful option as a substitute for 
aprepitant especially in patients aged > 50 years                                                                
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